Active uncontrolled bleeding
Clinically significant bleeding event within the last  months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
Significant GI or variceal bleeding or subdural hematoma within  months of the first dose of study drug
Variceal bleeding within  month prior to study registration
Subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within  year prior to the first dose of study drug
Significant bleeding disorders within  months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade  (per CTCAE version .)\r\n* Hemoptysis or other pulmonary bleeding >= grade  (per CTCAE version .)\r\n* Hematuria or other genitourinary bleeding >= grade  (per CTCAE version .)
Active bleeding conditions
If receiving warfarin: INR ? . and no active bleeding (i.e., no bleeding within  days prior to first dose of study therapy).
Patients must not have a significant history of bleeding events\r\n* Patients with a history of a significant bleeding episode (e.g. hemoptysis, upper or lower gastrointestinal (GI) bleeding, grade  or  gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within  months of registration are not eligible
The patient has uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past  months, such as hemoptysis, epistaxis, hematochezia, hematuria, or gastrointestinal bleeding.
Personal history of endometrial cancer or any abnormal uterine bleeding
Major bronchial occlusion or bleeding not amenable to palliation
COHORT B, GROUP : HEPATOCELLULAR CARCINOMA: Variceal bleeding within last  months
Presence of GI bleeding.
Known or suspected clinically significant active bleeding.
Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding
Bleeding disorders or active significant bleeding (i.e. hemoptysis, hematochezia, hematemesis) within  weeks
For cohort , any major bronchial occlusion or bleeding not amenable to palliation
For cohort , clinically significant hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding  months that were not related to glioma surgery; history of prior intratumoral bleeding is not an exclusion criterion; however, patients with a history of prior intratumoral bleeding, will need to undergo a non-contrast head computed tomography (CT) to exclude acute bleeding
Hospitalized patients (or willing to be hospitalized for  hours after Rx) with Modified WHO Grade  (subset) or Grade  Bleeding Score or at risk for same within  weeks of screening. The Grade  subset includes patients who have either epistaxis, hematuria, oral petechiae, or bleeding at invasive or other wound sites.
Patients with history of intra-abdominal bleeding or retroperitoneal bleeding within the last  years are excluded
Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of clinically significant bleeding
Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within  year prior to the first dose of study drug
Known inherited predisposition to bleeding or thrombosis
Platelet count > , cells/mm^ ( x ^/L) without transfusion support; evidence of mucosal bleeding; a known bleeding episode within  months of screening; or a history of a bleeding disorder
Uncontrolled or severe coagulopathies or a history of clinically-significant bleeding within the past  months, including any of the following, but not limited to:\r\n* Epistaxis\r\n* Hemoptysis\r\n* Hematochezia\r\n* Hematuria\r\n* Gastrointestinal bleeding\r\n* Spontaneous or tumor related intracranial hemorrhage
Known inherited predisposition to bleeding or thrombosis
Significant bleeding disorders within  months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding > grade  \r\n* Hemoptysis or other pulmonary bleeding > grade  \r\n* Hematuria or other genitourinary bleeding > grade 
No active bleeding
Major bleeding within the last  months.
No bleeding from gastrointestinal ulcers or other sites of bleeding
For subjects with CNS involvement (primary tumor or metastatic disease), have any active bleeding or new intratumoral hemorrhage of more than punctuate size of screening MRI obtained within  days of starting study drug or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
Active and significant bleeding
Active bleeding diathesis or history of major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within the past  months
Known inherited predisposition to bleeding or thrombosis
Subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within  year prior to the first dose of study drug
Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses, unless specifically occurring as an isolated incident during reversible chemotherapy-induced thrombocytopenia
Clinically significant hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding  months that were not related to glioma surgery; history of prior intratumoral bleeding is not an exclusion criteria; patients who with history of prior intratumoral bleeding, however, need to undergo a non-contrast head computed tomography (CT) to exclude acute bleeding
Patients with a history of bleeding disorders or evidence of intracranial abnormalities which would put them at risk for bleeding with anti-coagulation (e.g., strokes, active metastases).
Clinically significant bleeding event within the last  months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis
Severe bleeding, hemoptysis, gastrointestinal hemorrhage, CNS bleeding, clinically significant hemorrhage or vaginal bleeding during the last  months
Lesions with underlying infection or clinically meaningful bleeding
Patients with active or prior digestive tract bleeding.
For subjects with CNS involvement (primary tumor or metastatic disease): Subjects must not have any active bleeding, or new intratumoral hemorrhage of more than punctate size on screening MRI or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
Known portal hypertension or history of variceal bleeding
Underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding =<  year prior to the registration
Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of clinically significant bleeding
Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within  year prior to the first dose of study drug
Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses, unless specifically occurring as an isolated incident during reversible chemotherapy-induced thrombocytopenia
Patients with bleeding disorders are ineligible due to lymph node removal possibly causing excessive bleeding; bleeding disorder will be defined by an INR level of > .
Uncontrolled hypertension, major bleeding, HIV infection, or recent acute\n             cardiovascular event
No evidence of active bleeding
No history of abnormal bleeding tendency
No history of abnormal bleeding tendency or predisposition to repeated infections
For subjects with CNS involvement (primary tumor or metastatic disease): Have any active bleeding, or new intratumoral hemorrhage of more than punctate size on Screening MRI obtained within  days of starting study drug,or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
History of active bleeding within the last  months requiring transfusion
History of CNS bleeding within  months of registration
Patients with active bleeding of the GI tract or patients who have symptoms associated with stomach irritation (known as gastritis).
Active bleeding diathesis or history of any major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within  months of enrollment
Any history of clinically meaningful variceal bleeding within the last three months.
A history of bleeding (i.e., hemoptysis, hematuria, gastrointestinal blood loss, epistaxis, or others with greater than Grade  according to NCI CTCAE Version .) within  month prior to beginning therapy or any clinical indications of current active bleeding.
Known inherited predisposition to bleeding or thrombosis
A thrombotic or hemorrhagic event <= months prior to screening (includes hemoptysis, Gastrointestinal (GI) bleeding, hematemesis, central nervous system hemorrhage, epistaxis, vaginal bleeding, cerebral infarction, transient ischemic attacks, myocardial infarction, angina, and coronary artery disease)
have experienced any bleeding episode considered life-threatening, or any Grade  or  GI/variceal bleeding episode in the  months prior to enrollment requiring transfusion or endoscopic or operative intervention
Active uncontrolled bleeding
Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within  weeks prior to randomization.
Known inherited predisposition to bleeding or thrombosis
For patients that are to undergo the tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past  months, as judged by the investigator.
Ongoing major bleeding,
History of active gastrointestinal (GI) bleeding or other major bleeding =<  months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded
Known inherited predisposition to bleeding or thrombosis
Significant history of bleeding events or pre-existing bleeding diathesis =<  months of randomization (unless the source of bleeding has been resected)
Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
Evidence of blood clotting or bleeding abnormalities
Has had significant bleeding/thrombosis in previous  weeks
Presence of transfusion-dependent thrombocytopenia or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding when thrombocytopenic
Significant bleeding disorders within  months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade  (per CTCAE version .)\r\n* Hemoptysis or other pulmonary bleeding >= grade  (per CTCAE version .)\r\n* Hematuria or other genitourinary bleeding >= grade  (per CTCAE version .)
History of major hemorrhage including gastrointestinal bleeding (grade -), pulmonary hemorrhage, or clinically significant hemoptysis (>  teaspoon [tsp] in  hours) within the last  years; patients with underlying conditions that predispose to bleeding, such as bleeding diathesis, known esophageal varices, or tumor involving major vessels, are also excluded
Active uncontrolled bleeding
Bleeding\r\n* Clinically significant bleeding, such as gross hematuria, gastrointestinal bleeding (excluding bleeding from rectal tumor), and hemoptysis within the  months before screening; if clinically significant bleeding has occurred within  months of screening but the cause has been identified and adequately treated (e.g., cystitis, ulcer), then this exclusion criterion does not apply\r\n* Minor biopsy-related bleeding lasting <  hours and resolved at least  week before Study Day  is allowed
Significant history of bleeding events or pre-existing bleeding diathesis, within  months of randomization (unless the source of bleeding has been resected)
Uncontrolled severe bleeding tendency or active GI bleeding
Active bleeding or bleeding susceptibility
History of bleeding (hemoptysis in excess of . mL or one-half teaspoon, hematuria, gastrointestinal [GI] blood loss, epistaxis, or others with greater than grade  according to Common Terminology Criteria for Adverse Events [CTCAE] version .) within  month prior to beginning therapy or any clinical indications of current active bleeding
Clinically significant bleeding within  weeks of screening defined as any grade  or grade  bleeding by WHO Bleeding Scale or any gastrointestinal (GI) bleeding or intracranial hemorrhage
Clinically significant bleeding such as gross hematuria, gastrointestinal bleeding and hemoptysis within  months prior to enrollment.
Recent history (within  year of first dose) of underlying, predisposing condition of bleeding or currently exhibits signs of bleeding
Known inherited predisposition to bleeding or thrombosis
Active bleeding disorders or clinical signs of bleeding (Grade ?).
No major surgery within  weeks prior to enrollment or history of gastrointestinal bleeding within  months prior to enrollment; no signs or symptoms of active bleeding or non-healing ulcer will be permitted at study entry; patients with central pulmonary tumors with evidence of bronchial invasion, or presenting with hemoptysis will be excluded
Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant hemoptysis within  months of enrollment. Subjects with bleeding secondary to underlying disease (including gastrointestinal (GI) perforation or fistula) that has been corrected by surgery or alternative procedure may be included.
Active bleeding that requires hospitalization during the screening period
History of unexplained bleeding episodes within  months of M dosing
Participants with a recent history (<  months) of a major bleed which will be defined as a symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level  grams/dL or more, or leading to transfusion of two or more units of whole blood or packed red cells
Prior treatment with a BTK inhibitor . Presence of transfusion-dependent thrombocytopenia or a history of bleeding disorders or clinical conditions (eg, gastrointestinal bleeding or constitutional disorders) that may increase risk of life-threatening bleeding when thrombocytopenic . History of stroke or intracranial hemorrhage within  months prior to signing the ICD . Medications that are strong inhibitors or inducers of CYPA/ (eg, itraconazole, ketoconazole, clarithromycin, ritonavir, phenytoin, pentobarbital, and rifampin) should be changed; subjects who cannot change these medications must be excluded.
Recent hemoptysis >. mL or serious bleeding from another site, known bleeding disorder or coagulopathy or therapeutic anti-coagulation
History of bleeding diasthesis
Ongoing major bleeding,
Endometrial bleeding
Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the  months before screening
Patients are excluded with history of recent <  months thromboembolic events, clinically significant bleedinggross hematuria, hemoptysis, or gastrointestinal bleeding, history of bleeding diathesis or hypercoagulable state, or prior exposure to chimeric antibodies
Active bleeding
Known inherited predisposition to bleeding or thrombosis
Patient has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding; the subject has a recent history of non-chemotherapy induced thrombocytopenic associated bleeding within  year prior to the first dose of study drug
Target bleeding site has moderate bleeding according to the Investigator's judgment.
The target bleeding site has a mild or severe bleeding.
If receiving warfarin: INR ? . (and no active bleeding, [i.e., no bleeding within  days prior to first dose of study therapy])
No active bleeding
No active bleeding
Active bleeding
Clinically significant gastrointestinal bleeding (bleeding requiring procedural intervention, eg. variceal banding, transjugular intrahepatic portosystemic shunt (TIPS) procedure, arterial embolization, topical coagulation therapy) within  months prior to first dose.
Active bleeding
Active bleeding that requires hospitalization during the screening period
No central lung metastases with excessive active bleeding
Inherited predisposition to bleeding or thrombosis
History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic events within  months, clinically significant or tumor-related hemoptysis, active gastrointestinal bleeding or ulcers or major injuries or surgery
Known predisposition to bleeding
Subject has ? grade  bleeding at the time of randomization
Active grade >=  bleeding at the time of randomization, including hematuria
History of grade  bleeding
No clinical signs active of bleeding
Patients with overt bleeding
Persistent oral bleeding: >  mL (estimated) per day
Active bleeding (grade  or higher) at the time of enrollment
History of intracranial bleeding at any time
Active bleeding
Any bleeding episode considered life-threatening, or any Grade  or  gastrointestinal bleeding episode in the  months prior to randomization requiring intervention.
Active or serious bleeding within two weeks of enrollment
Recent acute bleeding requiring intervention in less than  hours
Active major bleeding
Women with active liver disease, abnormal uterine bleeding, or prior diagnosis of endometrial hyperplasia
Grade  or higher recent (within the past  months) or ongoing bleeding events
Active bleeding condition (not limited to: thrombocytopenia, hemophilias, potential bleeding lesions, recent trauma or surgery, recent stroke, confirmed intracranial or intraspinal bleeding)
History of major bleeding with bronchoscopy
Major surgery or significant bleeding episodes within  days before study initiation\r\n* Major surgery does not include: breast or other biopsies obtained for diagnosis, placement of radio-opaque clip to localize a tumor or tumors for subsequent surgical resection, placement of central venous access, pretreatment lymph node sampling\r\n* Significant bleeding episodes are defined for the purpose of this study as hemoptysis or upper/lower gastrointestinal bleeding\r\n* Although bevacizumab will be administered in tracer quantities in this study and is not expected to have pharmacologic effects, participants with major surgery or significant bleeding episodes within  days before study initiation may be at a higher risk of bleeding
Active vaginal bleeding requiring packing and emergent radiation therapy
No active bleeding
Bleeding and Thrombosis:
If active bleeding requiring acute surgical intervention, not eligible
The patient has uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past  months, such as hemoptysis, epistaxis, hematochezia, hematuria, or gastrointestinal bleeding.
